Akorn Signs Supply Pact with Fresenius Kabi

Akorn, Inc. has signed a five-year supply agreement with Fresenius Kabi for a new premix product. Premix medications are ready to use intravenous drug products.
   
Under the terms of the agreement, Akorn will be responsible for development, marketing and distribution of the premix product. Fresenius Kabi will manufacture the product at its intravenous solutions manufacturing facility in Halden, Norway. The product is expected to launch in 2012. Akorn will own the ANDA. Financial terms of the agreement were not disclosed.
   
Arthur S. Przybyl, Akorn’s president and chief executive officer, stated, “We look forward to partnering with Fresenius Kabi on this novel premix product. Additional niche products will be added that provide unique market value and fulfill customer needs.”